TSE:I Intellipharmaceutics International (I) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free I Stock Alerts C$3.23 +0.04 (+1.25%) (As of 03/17/2017) Add Compare Share Share Today's RangeC$3.15▼C$3.2650-Day RangeC$3.23▼C$3.2352-Week RangeC$1.78▼C$4.50Volume7,625 shsAverage Volume16,872 shsMarket CapitalizationC$97.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Intellipharmaceutics International alerts: Email Address Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… About Intellipharmaceutics InternationalIntellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.Read More I Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart I Stock News HeadlinesApril 22, 2024 | finance.yahoo.comSuper Generics Market Size Will Reach USD 128.62 Billion to 2031 - Revealed InsightAce Latest StudyFebruary 19, 2024 | theglobeandmail.comIntelliPharmaCeutics Intl: Top 10 Undervalued Biotechnology Industry Stocks (IPCI)April 23, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.January 3, 2024 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc up on Wednesday (IPCI)December 7, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc up on Tuesday (IPCI)October 16, 2023 | msn.comIntellipharmaceutics International GAAP EPS of -$0.06October 13, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc down on Friday (IPCI)July 6, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc down on Wednesday (IPCI)April 23, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.June 29, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc down on Tuesday (IPCI)June 13, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc down on Monday (IPCI)April 18, 2023 | finance.yahoo.comIntellipharmaceutics International Inc. (I4AA.F)April 7, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc flat on Wednesday (IPCI)April 5, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc flat on Monday (IPCI)April 4, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc flat on Friday (IPCI)February 7, 2023 | yahoo.comIntellipharmaceutics Provides Update on Management Cease Trade Order Application and Anticipates Cease Trade OrderJanuary 13, 2023 | finance.yahoo.comIntellipharmaceutics International Inc. (IPCIF)August 30, 2022 | thestreet.comChanges at the Top for Endo Could Benefit Its Smaller PartnersAugust 23, 2022 | reuters.comIntellipharmaceutics International IncJuly 23, 2022 | finanznachrichten.deIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Second Quarter 2022 ResultsJuly 21, 2022 | finance.yahoo.comIntellipharmaceutics Announces Second Quarter 2022 ResultsJuly 15, 2022 | ca.finance.yahoo.comStocks in play: Intellipharmaceutics International Inc.April 14, 2022 | finanznachrichten.deIntellipharmaceutics International Inc.: Intellipharmaceutics Announces First Quarter 2022 ResultsApril 14, 2022 | stockhouse.comIntellipharmaceutics Announces First Quarter 2022 ResultsFebruary 28, 2022 | finanznachrichten.deIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Fiscal Year 2021 ResultsJanuary 13, 2022 | finanznachrichten.deIntellipharmaceutics International Inc.: Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene KeirsteadJanuary 7, 2022 | nasdaq.comIntellipharmaceutics International Inc (IPCIF)See More Headlines Receive I Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Next Earnings (Estimated)6/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorBusiness Services Industry Wireless Telecommunications Sub-IndustryN/A Current SymbolTSE:I CUSIPN/A CIKN/A Webwww.intelsat.com Phone+1-416-7983001FaxN/AEmployees1,195Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares30,156,000Free FloatN/AMarket CapC$97.40 million OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesIsa Odidi Ph.D.Chairman of the Board, Chief Executive OfficerAmina Odidi Ph.D.President, Chief Operating Officer, DirectorAndrew PatientChief Financial OfficerJohn N. AllportVice President - Legal Affairs and Licensing, Secretary, DirectorPatrick N. Yat Ph.D.Vice President - Pharmaceutical Analysis and ChemistryKenneth KeirsteadIndependent DirectorBahadur MadhaniIndependent DirectorEldon R. Smith M.D. (Age 75)Independent Director More ExecutivesKey CompetitorsCIBT Education GroupTSE:MBANeuLionTSE:NLNZCL CompositesTSE:ZCLReitmansTSE:RETCO2 SolutionsCVE:CSTView All Competitors I Stock Analysis - Frequently Asked Questions How have I shares performed in 2024? Intellipharmaceutics International's stock was trading at C$3.23 at the beginning of 2024. Since then, I shares have increased by 0.0% and is now trading at C$3.23. View the best growth stocks for 2024 here. When is Intellipharmaceutics International's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our I earnings forecast. What other stocks do shareholders of Intellipharmaceutics International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intellipharmaceutics International investors own include QuickLogic (QUIK), VBI Vaccines (VBIV), NeuLion (NLN), Micron Technology (MU), Mallinckrodt (MNK), Intellipharmaceutics International (IPCIF), Fitbit (FIT), Clean Commodities (CLE), Calithera Biosciences (CALA) and BlackBerry (BB). How do I buy shares of Intellipharmaceutics International? Shares of I stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:I) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellipharmaceutics International Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
